The primary objectives of the Task Force were confirmed: to serve as an interface between the disciplines of oncology and allergy, covering: (i) basic, (ii) translational, (iii) epidemiological and (iv) clinical research, including allergy problems in clinical oncology, as well as (v) mechanisms of tumour‐induced immune modulation and (vi) novel vaccination and immunotherapy approaches harnessing IgE functions to target cancer. The gene discussed is IGHE; the disease is neoplasm.